Información de Edwards Lifesciences Corp, dividendo de Edwards Lifesciences Corp, actividades de los accionistas y más

Más Datos de Edwards Lifesciences Corp Compañía

Edwards Lifesciences Corporation is a global structural heart innovation company. The Company is engaged in patient-focused medical innovations for structural heart disease and invests in research and development to transform care for those impacted by structural heart disease. Its products are categorized into groups, including Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart (Surgical). It develops transcatheter heart valve replacement technologies designed for the minimally invasive replacement of aortic heart valves. The Edwards SAPIEN family of valves includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra, and the Edwards SAPIEN 3 Ultra RESILIA systems, are catheter-based approaches for treating severe symptomatic aortic stenosis. Its PASCAL PRECISION and Cardioband transcatheter valve repair systems are commercially available in Europe for mitral and tricuspid valve repair.

Información de la empresa

Símbolo de cotizaciónEW

Nombre de la empresaEdwards Lifesciences Corp

Fecha de salida a bolsaMar 27, 2000

Director ejecutivoMr. Bernard J. Zovighian

Número de empleados15800

Tipo de seguridadOrdinary Share

Fin del año fiscalMar 27

DirecciónOne Edwards Way

CiudadIRVINE

Bolsa de valoresNYSE Consolidated

PaísUnited States of America

Código postal92614

Teléfono19492502500

Sitio Webhttps://www.edwards.com

Símbolo de cotizaciónEW

Fecha de salida a bolsaMar 27, 2000

Director ejecutivoMr. Bernard J. Zovighian

Ejecutivos de la empresa

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Scott B. Ullem

Chief Financial Officer, Corporate Vice President

282.82K

+3.48%

Mr. Steven R. (Steve) Loranger

Independent Director

76.00K

+6.56%

Mr. Bernard J. Zovighian

Chief Executive Officer, Director

39.57K

+120.44%

Mr. Daniel J. Lippis

Corporate Vice President - Transcatheter Aortic Valve Replacement

21.26K

-17.30%

Mr. Daveen Chopra

Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies

19.91K

+19.18%

Mr. Paul A. Laviolette

Independent Director

11.25K

+45.71%

Dr. David T. Feinberg, M.D.

Independent Director

5.84K

+152.86%

Mr. Nicholas J. (Nick) Valeriani

Independent Chairman of the Board

--

Mr. Kieran T. Gallahue

Independent Director

--

Mr. Donald E. Bobo, Jr.

Corporate Vice President - Strategy and Corporate Development

--

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Scott B. Ullem

Chief Financial Officer, Corporate Vice President

282.82K

+3.48%

Mr. Steven R. (Steve) Loranger

Independent Director

76.00K

+6.56%

Mr. Bernard J. Zovighian

Chief Executive Officer, Director

39.57K

+120.44%

Mr. Daniel J. Lippis

Corporate Vice President - Transcatheter Aortic Valve Replacement

21.26K

-17.30%

Mr. Daveen Chopra

Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies

19.91K

+19.18%

Mr. Paul A. Laviolette

Independent Director

11.25K

+45.71%

Desglose de ingresos

Divisa: USDActualizado: dom., 6 de jul

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

FY2017

FY2016

FY2015

Por negocioUSD

Nombre

Ganancia

Proporción

Transcatheter Aortic Valve Replacement

1.05B

74.09%

Surgical Heart Valve Therapy

250.90M

17.76%

Transcatheter Mitral and Tricuspid Therapies

115.20M

8.15%

Por regiónUSD

Nombre

Ganancia

Proporción

United States

838.90M

59.38%

Europe

341.80M

24.19%

Rest of the world

150.20M

10.63%

Japan

81.80M

5.79%

Por negocio

Por región

Por negocioUSD

Nombre

Ganancia

Proporción

Transcatheter Aortic Valve Replacement

1.05B

74.09%

Surgical Heart Valve Therapy

250.90M

17.76%

Transcatheter Mitral and Tricuspid Therapies

115.20M

8.15%

Estadísticas de accionistas

Actualizado: sáb., 16 de ago

Accionistas

Tipos de accionistas

Accionistas

Proporción

The Vanguard Group, Inc.

11.88%

BlackRock Institutional Trust Company, N.A.

5.26%

State Street Global Advisors (US)

4.37%

JP Morgan Asset Management

3.42%

Wellington Management Company, LLP

3.38%

Otro

71.70%

Accionistas

Proporción

The Vanguard Group, Inc.

11.88%

BlackRock Institutional Trust Company, N.A.

5.26%

State Street Global Advisors (US)

4.37%

JP Morgan Asset Management

3.42%

Wellington Management Company, LLP

3.38%

Otro

71.70%

Tipos de accionistas

Accionistas

Proporción

Investment Advisor

43.47%

Investment Advisor/Hedge Fund

29.29%

Hedge Fund

6.66%

Research Firm

2.13%

Pension Fund

2.13%

Bank and Trust

1.93%

Sovereign Wealth Fund

1.35%

Individual Investor

0.92%

Endowment Fund

0.82%

Otro

11.29%

Participación institucional

Actualizado: mar., 1 de jul

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q2

2595

528.14M

89.95%

-20.66M

2025Q1

2628

535.29M

91.24%

-19.91M

2024Q4

2597

531.64M

90.42%

-4.10M

2024Q3

2568

511.38M

84.93%

-20.94M

2024Q2

2559

522.19M

86.68%

-12.58M

2024Q1

2572

518.82M

86.18%

-12.08M

2023Q4

2573

509.93M

84.08%

-27.42M

2023Q3

2530

522.96M

86.03%

-18.75M

2023Q2

2517

523.54M

86.35%

-20.02M

2023Q1

2495

522.98M

86.26%

-32.79M

Actividad de los accionistas

Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

The Vanguard Group, Inc.

68.94M

11.75%

+70.46K

+0.10%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

32.28M

5.5%

+544.18K

+1.71%

Mar 31, 2025

State Street Global Advisors (US)

25.78M

4.4%

-25.16K

-0.10%

Mar 31, 2025

JP Morgan Asset Management

16.37M

2.79%

+5.61M

+52.12%

Mar 31, 2025

Wellington Management Company, LLP

29.13M

4.97%

-4.08M

-12.27%

Mar 31, 2025

Citadel Advisors LLC

13.38M

2.28%

+3.96M

+42.09%

Mar 31, 2025

Geode Capital Management, L.L.C.

12.68M

2.16%

-970.48K

-7.11%

Mar 31, 2025

Jennison Associates LLC

10.09M

1.72%

+2.58M

+34.31%

Mar 31, 2025

Walter Scott & Partners Ltd.

9.06M

1.54%

-347.38K

-3.69%

Mar 31, 2025

ETFs relacionados

Actualizado: sáb., 6 de sep

Nombre

Proporción

iShares U.S. Medical Devices ETF

4.91%

Future Fund Long/Short ETF

3.53%

iShares Health Innovation Active ETF

3.33%

Hennessy Sustainable ETF

3.29%

Global X Aging Population ETF

3.19%

First Trust Indxx Medical Devices ETF

2.24%

SPDR S&P Health Care Equipment ETF

2.05%

Brown Advisory Flexible Equity ETF

1.99%

Tema Heart & Health ETF

1.93%

Invesco S&P 500 Equal Weight Health Care ETF

1.84%

iShares U.S. Medical Devices ETF

Proporción4.91%

Future Fund Long/Short ETF

Proporción3.53%

iShares Health Innovation Active ETF

Proporción3.33%

Hennessy Sustainable ETF

Proporción3.29%

Global X Aging Population ETF

Proporción3.19%

First Trust Indxx Medical Devices ETF

Proporción2.24%

SPDR S&P Health Care Equipment ETF

Proporción2.05%

Brown Advisory Flexible Equity ETF

Proporción1.99%

Tema Heart & Health ETF

Proporción1.93%

Invesco S&P 500 Equal Weight Health Care ETF

Proporción1.84%

Dividendos

Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Sin datos

División de acciones

Fecha

Tipo

Relación

May 07, 2020

Split

1→3

Fecha

Tipo

Relación

May 07, 2020

Split

1→3

Edwards Lifesciences Corp

75.090USD

Edwards Lifesciences Corp

75.090

Descripción general

Compañía

Finanzas

Análisis